Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

PEGCETACOPLAN vs RAVULIZUMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

PEGCETACOPLAN vs RAVULIZUMAB: Safety Overview

Metric PEGCETACOPLAN RAVULIZUMAB
Total FAERS Reports 1,369 118
Deaths Reported 84 11
Death Rate 6.1% 9.3%
Hospitalizations 252 89
Average Patient Age 65.4 yrs 48.4 yrs
% Female Patients 70.5% 56.3%
FDA Approval Date Feb 17, 2023 N/A
Manufacturer Apellis Pharmaceuticals, Inc. Alexion Pharmaceuticals Inc.
Route SUBCUTANEOUS INTRAVENOUS
Marketing Status Prescription N/A